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Abstract: Determining subjects with heart failure (HF), who have a high risk of 
developing atrial fibrillation (AF), is crucial since it is related to an increase in 
morbidity and mortality. The importance of an increase in inflammatory response 
cannot be ignored in developing AF in subjects with HF. This study’s goal was to 
evaluate the relationship between the development of AF and monocyte count, the 
main components of the inflammatory response, in subjects with HF. Medical data of 
158 subjects in total with sinus rhythm, admitted to the emergency department and 
hospitalized with systolic HF between January 2009 and February 2014, were 
analyzed prospectively. All the subjects followed up in terms of the development of 
AF. The subjects separated into two groups according to their rhythm at the end of 
the follow-up period. Group 1 included subjects who maintained sinus rhythm, while 
Group 2 included subjects with AF. Echocardiographic findings and laboratory data 
were collected. No statistically significant difference was determined between the 
groups concerning age, sex (p=0.056), hypertension, diabetes mellitus, and smoking 
status. The two groups differed significantly regarding the presence of moderate-to-
severe mitral regurgitation (MR) [32 (28%) vs. 22 (51%), p=0.010] and monocyte 
count [560 (20-3100) vs. 800 (380-1510) μL, p<0.001]. The multivariate Cox 
regression model demonstrated that an association of monocyte count (HR=2.397, 
95% CI =1.397-4.112, p=0.002) and moderate-to-severe MR (HR= 2.347, 95% 
CI=1.276-4.316, p=0.006) with the development of AF remained following the 
adjustment for the variables, which had determined to be statistically significant as a 
result of the univariate analysis and related to monocyte count. The present study 
concludes that increased monocyte count in subjects with HF is related to the 
development of AF. However, further large-scale research required for confirming 
the findings, as mentioned above. 
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INTRODUCTION 
Monocytes account for approximately one-fifth of mononuclear cell fragments 
in the peripheral blood, and they are essential for inflammatory 
response.(Curi,2017;Acikgoz 2018) Monocytes take a significant place in 
inflammatory processes and the occurrence of cardiovascular diseases by promoting 
the release of immunostimulatory agents, cytokines, growth factors, platelet-derived 
activation products, oxidized lipids, and eicosanoid proteins. (Gratchev,2012) 
Monocytes and macrophages result in the release of cytokines that are involved in 
atrial fibrosis and remodeling the development of atrial fibrillation (AF), as in the case 
of many other cardiovascular diseases. (Takahashi, 2012) 
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Atrial fibrillation represents the arrhythmia type, which is common in heart 
failure (HF), and its prevalence can reach 30% in HF(Kotecha,2015). 
Moreover, atrial fibrillation is an independent indicator of mortality and 
morbidity in HF(Carlisle,2019). It is, therefore, essential to recognize subjects with 
HF, who carry a high risk of the development of AF. Inflammation, oxidative stress, 
and neurohormonal activation are the main physiopathological pathways in 
developing AF in subjects with HF ( January 2014) Several studies have shown 
elevated levels of interleukin (IL)-22, IL-6, IL-8, and tumor necrosis factor-alpha 
(TNF-α) as inflammatory biomarkers, the production of which involves monocytes 
and macrophages in patients with AF(Oikonomou,2019; Zacharia,2019) 
Previous research has shown an association between monocyte count and 
all-cause mortality, hospitalization, and the New York Heart Association (NYHA) 
class (Elchinova,2018; Dixon,2011). Nevertheless, there is no research showing a 
correlation between monocyte count and the development of AF in subjects with HF. 
The present research aimed to examine the correlation between monocyte count 
and the development of AF in subjects with systolic HF. 
 
MATERIALS AND METHOD 
In our study, the prospective screening of 210 patients with HF, admitted to 
the emergency department and hospitalized due to systolic HF, was performed. The 
following exclusion criteria were determined: acute coronary syndrome, cancer, 
active inflammatory diseases, infectious diseases, sepsis, and myeloproliferative 
disorders. Finally, 158 patients with systolic HF enrolled in the research. All study 
procedures were approved by the ethics committee of Cumhuriyet University (Sivas, 
TURKEY), according to the Declaration of Helsinki. Written informed consent 
obtained from all subjects. 
Systolic HF was diagnosed based on the compatible clinical presentation and 
history combined with documented systolic left ventricular (LV) dysfunction that 
described as an LV ejection fraction (LVEF) less than 50% in echocardiography. 
The subjects followed up for the development of AF. The subjects separated 
into two groups according to their rhythm at the end of the follow-up period. Group 1 
consisted of subjects who maintained sinus rhythm, while Group 2 included subjects 
with AF. A comparison between the two groups made in terms of echocardiographic 
parameters and laboratory data, and cardiovascular risk factors, such as diabetes 
mellitus (DM), hypertension (HT), and smoking status. Hypertension described as 
blood pressure higher than 140/90 mmHg on more than two occasions in the course 
of office measurements or receiving antihypertensive therapy. Diabetes mellitus 
described as a fasting blood sugar level higher than or equal to 126 mg/dL or 
undergoing antidiabetic therapy. 
Expert echocardiographers performed echocardiographic examinations using 
the Vivid seven system (GE Healthcare, Milwaukee, WI, USA) and 2.5–5 MHz 
probes. Digital recordings of echocardiographic examinations assessed offline. The 
LVEF computed by employing the modified Simpson method. Chamber sizes 
determined following the recently published guidelines. The measurement of the LA 
size was performed at the end-ventricular systole by the M-mode linear dimension, 
acquired from the parasternal long-axis view. Systolic pulmonary artery pressure 
(sPAP) was computed, as described elsewhere (Galderisi,2017). 
The grading of valvular regurgitations was performed in two categories, being 
0moderate-to-severe vs. not moderate-to-severe, as a result of combining color flow 
jet Doppler signal intensity and vena contracta width following the guideline 
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RESULTS AND DISCUSSION 
 The follow-up of all the subjects was performed for a mean period of 22.1±11 
months (range 4–61). The subjects separated into two groups according to their 
rhythm at the end of the follow-up period. Group 1 consisted of patients who 
maintained sinus rhythm, while Group 2 included patients who developed AF. Table 
1 presents information on baseline features, echocardiographic parameters, and 
laboratory data. No statistically significant difference was detected between the two 
groups concerning age, sex (P=0.056), HT, DM, and smoking status. 
 
Table 1. Baseline Characteristics of Study Patients 
                                                                                                                       








Age (yr) 69 ± 10 68±11 70 ±9 0,339 
Female                                            41 (%26) 35(%30) 6(%14) 0,057 
Hypertension                                  83(%53) 56(%49) 27(%63) 0,114 
Diabetes mellitus                            46(%29) 30(%26) 16(%37) 0,241 
Current smoking                             54 (%34) 41(%36) 13(%30) 0,652 
Echocardiographic findings 
LVEF (%)                                            30,9±8,2 30,3±8,1 32,4±8,5 0,158 
LA(cm)                                          4,5 ±0,6 4,4±0,6 4,5±0,7 0,395 
SPAP (mmhg)                                34±12 33±12 34±12 0,689 
Moderate-severe MR                   54(%34) 32(%28) 22(%51) 0,010 
Moderate-severe TR 57(%36) 37(%32) 20(%46) 0,095 
Laboratory findings 
Hemoglobin (g/dL)                        13,0±2,5 13,0±2,6 13,1±2,4 0,875 
BUN(mg/dL)                                                         25(8-103) 24(8-103) 27(11-81) 0,700 
Creatinine (mg/dL)                             1,1(0,5-5,7) 1,1(0,5-5,70) 1,3(0,6-2,4) 0,524 














Monocyte   cells/μl                    600(20-
3100) 
560(20-3100) 800(380-1510) <0,001 





Eosinophil cells/μl                                                                                                                                                                                    105 (0-
1260) 
100(0-1260) 130(0-970) 0,269 
Platelet      103x 
cells/μl                                                                                                                                                                                                                       
238±84 235±80 248±94 0,376 
Abbreviations: SPAP, systolic pulmonary artery pressure; LA, left atrial diameter; 
MR, mitral regurgitation; SR, sinus rhythm; AF, atrial fibrillation; TR, tricuspid 
regurgitation; LVEF, left ventricle ejection fraction; BUN, blood urea  nitrogen; WBC, 
white blood cell 
 The two groups differed significantly regarding the presence of moderate-to-
severe mitral regurgitation (MR) [32 (28%) vs. 22 (51%), p=0.010] and monocyte 
count [560 (20-3100) vs. 800 (380-1510) μL, p<0.001]. As expected, monocyte count 
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and white blood count, neutrophil, and lymphocyte count were positively correlated 
(Table 2). 
 Table 3 presents the findings obtained from the univariate and multivariate 
Cox regression analyses for the development of AF. In the univariate analysis, an 
association revealed between moderate-to-severe MR and monocyte count and the 
development of AF. Furthermore, the multivariate Cox regression model 
demonstrated that an association of monocyte count (HR =2.397, 95% CI =1.397-
4.112, p=0.002) and moderate-to-severe MR (HR= 2.347, 95% CI =1.276-4.316, 
p=0.006) with the development of AF remained following the adjustment for the 
variables, which had been determined to be statistically significant in the univariate 
analysis and related to monocyte count. 
 
Table 2. Spearman Correlation Coefficients for Monocyte Count 
 
Variable Monocyte Count p-value 
WBC 0,591 <0,001 
Neutrophil 0,472 <0,001 
Lymphocyte 0,324 <0,001 
         Abbreviations: WBC; white blood cell 
 
Table 3. Univariate and Multivariate Analyses for Predicting Atrial Fibrillation 
 
 Univariate Multivariate 
Variable p HR (95% Cl) P HR (95% Cl) 
Statistically significant variables 
Monocyte 0,003 2,189 1,308-3,665 0,002 2,397 1,397-4,112 
Moderate - severe MR 0,010 2,196 1,204-4,006 0,006 2,347 1,276-4,316 
Variables correlated with monocyte count 
WBC 0,354 0,960 0,880-1,047    
Neutrophil 0,384 0,960 0,875-1,053    
Lymphocyte 0,532 1,106 0,807-1,514    
 
In the present research, an independent association of elevated monocyte 
counts with the development of AF determined in subjects with HF. 
Heart failure represents a complex syndrome accompanied by hemodynamic 
and neurohormonal disturbances, involving the release of various cytokines, 
sympathetic nervous system activation, and the activation of the renin-angiotensin-
aldosterone system (Ponikowski P,2016). Atrial fibrillation represents the arrhythmia 
type that most frequently observed in subjects with HF, and HF subjects with AF 
have a poorer prognosis than subjects maintaining sinus rhythm (Wang,2003; 
Carlisle,2019). It is, therefore, significant to determine subjects at high risk of 
developing AF. Much research has demonstrated that atrial and ventricular wall 
stress plays a significant role in developing AF(Yang, 2014; Cullington,2014). 
On the other hand, inflammation takes a central part in the pathophysiology of 
the development of AF, as in many cardiovascular diseases. Several studies have 
indicated elevated levels of inflammatory biomarkers, including IL-2, IL-6, IL-8, and 
TNF-α, in subjects with AF (Conway,2004; Zacharia,2019). 
 Monocytes are the primary cell line involved in the inflammatory response, 
although they constitute only 5 to 10% of leukocytes in the peripheral blood. 
Monocytes increase inflammatory response by secreting cytokines, on the one hand, 
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and they increase their cell fragments, on the other hand (Franca,2017; 
Kratofil,2017). Previous studies have revealed the clinical significance of monocyte 
activation and increased monocyte count in cardiovascular diseases, such as stable 
coronary artery disease, stroke, and HF(Rogacev,2012; Kim,2014; Wrigley,2011). 
The importance of monocyte activation for the development and progression of HF 
has been shown (Wrigley,2011; Shahid,2018). 
Furthermore, proinflammatory and anti-inflammatory cytokines, such as IL-6, 
TNF-α, and IL-10, for which activated monocytes are the primary source, have been 
demonstrated to correlate with the progression and severity of HF and the 
associated mortality (Wrigley,2011; Shirazi, 2017; Bartekova,2018). However, no 
previous study has evaluated the relationship between monocyte count and 
developing AF in subjects with HF. As far as we know, the current research 
represents the first study demonstrating an association of the high monocyte count 
with the development of AF in subjects with HF. In a study, Karatas et al. found a 
relationship between monocyte count and the development of AF(Karatas,2016). 
Another study found a relationship between monocyte activation and AF 
development following cardiac surgery(Tekkesin,2017). Observational and ex vivo 
studies also demonstrated a relationship between AF and inflammation and oxidative 
stress-mediated by monocytes(January 2014). Endomyocardial biopsies obtained 
from the right atrial septum of patients with AF showed the widespread inflammatory 
infiltrates of monocytes (Smorodinova,2017). Deng et al. showed that monocytes 
attach to adhesion molecules that proceed into the sub-endothelial space of the atrial 
wall, by producing cytokines including TNF-a and IL-6, which can be associated with 
the mechanism of AF development (Deng,2011). 
On the other hand, monocytes secrete various cytokines that are closely 
related to the development of AF, and these cytokines play a central role in atrial 
remodeling by affecting myocytes and fibroblasts in the atrial tissue 
(Takahashi,2012; Li,2010; Guo,2012). According to the findings obtained from this 
research, monocyte activation induced by various causes in patients with HF may 
cause AF through an escalated inflammatory process. 
In the present study, we also showed that the development of AF in subjects 
with HF could be predicted by moderate-to-severe MR, as expected. Similar to the 
data reported in previous studies, the current research also found a relationship 
between the severity of MR and the development of AF (Yokota,2018; Grigoini 
2018). This finding may be associated with an increase in the left atrial diameter 
resulting from the increasing severity of MR and atrial fibrosis, which is the source of 
reentry resulting in AF. 
The present research represents a single-center study, which has a 
comparatively small sample size. Another limitation is that the present study did not 
create subsets and perform the functional analysis of peripheral monocytes. 
Cytokine analysis could not be performed in the study due to its high cost. Although 
patients with active inflammatory disease, infectious disease, sepsis, or 
myeloproliferative disorders excluded from the study, it is another limitation of the 
present study that other inflammatory clinical problems, which could increase 
monocyte count, may have been possibly overlooked. 
 
CONCLUSION 
 In conclusion, our study results suggest that there is an association of the high 
monocyte count with the development of AF in subjects with HF. Therefore, we 
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recommend that subjects with HF and increased monocyte count should strictly be 
monitored for the development of AF. 
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